Syneron Bio Pulls $150M Series B Four Months After $100M Round

Syneron Bio closed a $150 million Series B — its second major raise in four months, bringing total funding to roughly $250 million since December.

Abu Dhabi’s sovereign wealth fund joined the cap table. AstraZeneca, already a partner and investor, came back in. The round was led by an unnamed international life sciences fund — the rest of the syndicate reads like a who’s who of Asia-Pacific life sciences capital.

Syneron locked a $3.4 billion biobucks deal with AstraZeneca in March 2025 — $75 million in upfront and near-term milestone payments, the rest in milestones — then raised nearly $100 million in December. Now $150 million more. The market’s pricing the macrocyclic peptide thesis hard, and Syneron is the clearest validation trade. Novartis isn’t sitting out either: it inked a deal potentially worth more than $1.7 billion with Unnatural Products in February for the same drug class.

Macrocyclic peptides sit between small molecules and biologics. They can hit targets that neither approach can reach alone, which is why pharma is buying platform access before clinical data arrives.

CEO Xiao Zhang said the Series B will advance oncology, autoimmune, metabolic and rare disease programs toward the clinic. Syneron was founded in 2022. It’s now sitting on roughly $250 million in raised capital and $3.4 billion in contingent AstraZeneca milestones.

— Diana Kowalski